DFDA

Dapagliflozin

Treatment for Alcoholic Cardiomyopathy

Typical Dosage: 10mg daily

Effectiveness
80%
Safety Score
65%
Clinical Trials
20
Participants
20K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
10mg daily
Time to Effect
4-8 weeks
Treatment Duration
lifetime
Evidence Quality
HIGH
Number Needed to Treat (NNT)
25(Treat 25 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$5,500
Monitoring:$300
Side Effect Mgmt:$100
Total Annual:$5,900
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$40,000/QALY
QALYs Gained
0.5
Outcome-Based Costs
Cost per Responder
$7,867
Comparison vs Placebo + Standard Care
Cost Difference
+$5,900/year
More expensive
QALY Difference
+0.50 QALYs
Better outcomes
Dominance
No dominance
Dapagliflozin Outcomes

for Alcoholic Cardiomyopathy

Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+75%
Common Side Effects
Genital mycotic infections
+8%
Urinary tract infections
+4%
Hypotension
+3%
Diabetic ketoacidosis (rare)
+0.1%

Sources:

nih.gov
nih.gov
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov